Novartis, a leading global innovative medicines company, today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. This purpose-built RLT site will be the company’s fifth in the US and first manufacturing facility in Texas, and marks further progress in the company’s $23 billion US investment. The Denton site is expected to create new Novartis jobs in bioengineering, advanced manufacturing, quality and oper

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients 6 years of age and older with allergic fungal rhinosinusitis ( AFRS ) who have a history of sinonasal surgery. The FDA evaluated Dupixent under a Priority Review for the treatment of AFRS. This review is reserved for drugs that represent significant improvements in the treatment, diagnosis, or prevention of serious conditions. This approval expands our approved indic

Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-nee

PlantArcBio, an ag-biotechnology company pioneering precision biology for better crop performance, and Helix Sementes e Biotecnologia, a corn and sorghum seed company within Agroceres Group, today announced a licensing collaboration to develop and commercialize novel corn traits designed to increase yield and improve drought resilience in key South American markets. Under the agreement, Helix has licensed PlantArcBio's proprietary genes associated with yield improvement and drou

SEQSTER PDM, Inc. the leading healthcare technology company and the data connection, collection, and orchestration layer for patient health data, today announced the launch of 1-Click Data Refinery™, an enterprise-grade data harmonization engine designed for pharmaceutical companies, contract research organizations, and healthcare enterprises. The solution transforms raw, patient-consented EHR data into clean, structured, AI-ready patient records that support rapid model training, real-

Asahi Kasei Pharma announces that it has selected MAIA Pharmaceuticals, Inc. as its U.S. partner under a strategic collaboration for the development and commercialization in the U.S. of Teribone™ osteoporosis drug (generic name: teriparatide acetate; product name in Japan: “Teribone™ 56.5 µg subcutaneous injection” and “Teribone™ 28.2 µg subcutaneous injection autoinjector”). Under the collaboration framework, MAIA will leverage

Tempus AI, Inc. a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous Recombination Deficiency (HRD), providing a more robust, functional assessment of tumor biology compared to traditional static DNA-based assays. Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients l

Sensei Biotherapeutics, Inc. today announced that it has acquired Faeth Therapeutics Inc. (“Faeth”), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The acquisition brings Faeth’s lead asset PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, into Sensei’s pipe

Pharmacelera, a deep tech company applying Quantum Mechanics and Artificial Intelligence to revolutionize drug discovery, has closed a €6 million investment round to accelerate its expansion in the United States and grow the capabilities of its proprietary platform. Utilizing its proprietary Quantum Mechanics and Artificial Intelligence ("QaiM") algorithms, Pharmacelera is revolutionizing drug discovery by finding novel and diverse molecular candidates across the vast

Twist Bioscience Corporation, a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra’s B-Body® bispecific antibody platform (“B-Body platform”), extending Twist’s an